192 related articles for article (PubMed ID: 24471573)
1. Ketoconazole in Cushing's disease: is it worth a try?
Castinetti F; Guignat L; Giraud P; Muller M; Kamenicky P; Drui D; Caron P; Luca F; Donadille B; Vantyghem MC; Bihan H; Delemer B; Raverot G; Motte E; Philippon M; Morange I; Conte-Devolx B; Quinquis L; Martinie M; Vezzosi D; Le Bras M; Baudry C; Christin-Maitre S; Goichot B; Chanson P; Young J; Chabre O; Tabarin A; Bertherat J; Brue T
J Clin Endocrinol Metab; 2014 May; 99(5):1623-30. PubMed ID: 24471573
[TBL] [Abstract][Full Text] [Related]
2. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing's disease.
van den Bosch OF; Stades AM; Zelissen PM
Clin Endocrinol (Oxf); 2014 Feb; 80(2):184-90. PubMed ID: 23841642
[TBL] [Abstract][Full Text] [Related]
3. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.
Castinetti F; Morange I; Jaquet P; Conte-Devolx B; Brue T
Eur J Endocrinol; 2008 Jan; 158(1):91-9. PubMed ID: 18166822
[TBL] [Abstract][Full Text] [Related]
4. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
5. Potential role for retinoic acid in patients with Cushing's disease.
Pecori Giraldi F; Ambrogio AG; Andrioli M; Sanguin F; Karamouzis I; Corsello SM; Scaroni C; Arvat E; Pontecorvi A; Cavagnini F
J Clin Endocrinol Metab; 2012 Oct; 97(10):3577-83. PubMed ID: 22851491
[TBL] [Abstract][Full Text] [Related]
6. Successful outcome of pregnancy in a patient with Cushing's disease under treatment with ketoconazole during the first trimester of gestation.
Boronat M; Marrero D; López-Plasencia Y; Barber M; Schamann Y; Nóvoa FJ
Gynecol Endocrinol; 2011 Sep; 27(9):675-7. PubMed ID: 20923280
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of Cushing's disease with ketoconazole].
Méndez Pérez P; Barrio Castellanos R; Núñez Estévez M; Pérez Rodríguez C; Hernández Doménech R
An Pediatr (Barc); 2009 Apr; 70(4):366-9. PubMed ID: 19282258
[TBL] [Abstract][Full Text] [Related]
8. Ketoconazole as an adrenal steroidogenesis inhibitor: effectiveness and risks in the treatment of Cushing's disease.
Newell-Price J
J Clin Endocrinol Metab; 2014 May; 99(5):1586-8. PubMed ID: 24802173
[No Abstract] [Full Text] [Related]
9. Course of pregnancies in women with Cushing's disease treated by gamma-knife.
Ferraù F; Losa M; Cotta OR; Torre ML; Ragonese M; Trimarchi F; Cannavò S
Gynecol Endocrinol; 2012 Oct; 28(10):827-9. PubMed ID: 22571755
[TBL] [Abstract][Full Text] [Related]
10. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
11. Apparent mineralocorticoid excess as a side effect of ketoconazole therapy in a patient with Cushing's disease.
Luque-Ramírez M; Ortiz-Flóres AE; Nattero-Chávez L; Escobar-Morreale HF
Clin Endocrinol (Oxf); 2020 Jan; 92(1):80-83. PubMed ID: 31667853
[No Abstract] [Full Text] [Related]
12. No Untoward Effect of Long-Term Ketoconazole Administration on Electrocardiographic QT Interval in Patients with Cushing's Disease.
De Martin M; Toja PM; Goulene K; Radaelli P; Cavagnini F; Stramba-Badiale M; Pecori Giraldi F
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):279-83. PubMed ID: 26386326
[TBL] [Abstract][Full Text] [Related]
13. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism.
Vignati F; Loli P
J Clin Endocrinol Metab; 1996 Aug; 81(8):2885-90. PubMed ID: 8768846
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
15. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
[TBL] [Abstract][Full Text] [Related]
16. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Vilar L; Naves LA; Azevedo MF; Arruda MJ; Arahata CM; Moura E Silva L; Agra R; Pontes L; Montenegro L; Albuquerque JL; Canadas V
Pituitary; 2010 Jun; 13(2):123-9. PubMed ID: 19943118
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
Barbot M; Albiger N; Ceccato F; Zilio M; Frigo AC; Denaro L; Mantero F; Scaroni C
Pituitary; 2014 Apr; 17(2):109-17. PubMed ID: 23468128
[TBL] [Abstract][Full Text] [Related]
20. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.
Feelders RA; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; van Heerebeek R; de Jong FH; van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
N Engl J Med; 2010 May; 362(19):1846-8. PubMed ID: 20463350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
